ClinicalTrials.gg
CompletedNCT00543855Updated Mar 8, 2013Results posted

A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431)

A Phase 2 interventional study of 3 mg Donepezil hydrochloride and 5 mg Donepezil hydrochloride in Dementia With Lewy Bodies (DLB), sponsored by Eisai Co., Ltd.. Completed at 43 sites in Japan. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2013-03-08.

Sponsored by Eisai Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
167
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of E2020 in patients with Dementia with Lewy Bodies (DLB).

02

Conditions studied

  • Dementia With Lewy Bodies (DLB)

Keywords

  • Lewy Body Disease
  • Dementia
  • Clinical Trial
  • Phase II
  • E2020
  • donepezil hydrochloride
03

In context

Lewy Body Disease

240 studies on the registry are indexed under Lewy Body Disease; 89 are open to participants now.

This study's enrollment of 167 is above the median of 86 across 152 interventional studies indexed under Lewy Body Disease.

Browse Lewy Body Disease studies →

Lead sponsor

Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients diagnosed as probable Dementia With Lewy Bodies (DLB) according to the diagnostic criteria for DLB.

Participants having caregivers who submit written consent for cooperative involvement in this study, can routinely stay with participants 3 days a week (at least 4 hours a day), provide participants' information necessary for this study, assist treatment compliance, and escort participants on required visits to study institution.

Exclusion criteria

Exclusion criteria:

Participants with past experience of donepezil (Aricept) therapy at the same study institution.

Participants treated with donepezil in 3 months immediately before starting the observation period.

Participants with a complication of serious neuropsychiatric disease(s) such as stroke, brain tumor, schizophrenia, epilepsia, normal pressure hydrocephalus, mental retardation, brain trauma with unconsciousness, and/or experience of brain surgery causing unsolved deficiency.

Participants with severe complication of cardiovascular, hepatic, renal, hematological, or other diseases unable to secure the safety.

Pregnant or lactating women, or women who are willing to become pregnant no later than 1 month after the scheduled study completion

Participants with severe extrapyramidal disorders (Hoehn \& Yahr staging score is ≥IV)

Participants whose systolic blood pressure is \<90 mmHg or pulse rate is \<50 beats/min.

Participants suspected to have a complication of vascular dementia based upon neurological findings.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
167 participants (actual)

Study arms

  • Experimental
    3 mg Donepezil hydrochloride

    Drug: 3 mg Donepezil hydrochloride

  • Experimental
    5 mg Donepezil hydrochloride

    Drug: 5 mg Donepezil hydrochloride

  • Experimental
    10 mg Donepezil hydrochloride

    Drug: 10 mg Donepezil hydrochloride

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks. Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast.

    Also known as: Aricept, Donepezil hydrochloride, E2020

  • Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks. Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks). Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 84 (10 weeks).

    Also known as: Aricept, Donepezil hydrochloride, E2020

  • Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks. Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks). Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 42 (4 weeks). Followed by two 5 mg Donepezil hydrochloride tablets (10 mg) by mouth, once daily after breakfast for Day 43 - Day 84 (6 weeks).

    Also known as: Aricept, Donepezil hydrochloride, E2020

  • DrugPlacebo

    Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks. Treatment Period: Two Donepezil hydrochloride Placebo tablets by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast.

06

What researchers measure

Primary outcomes

  1. Cognitive Function: Change From Baseline in Mini-mental State Examination (MMSE) Total at Week 12 Last Observation Carried Forward (LOCF)

    MMSE measured general cognitive functioning: orientation, memory, attention, calculation, language, visuospatial functions. Total score derived from sub-scores; total ranged from 0 - 30, where a higher score indicated better cognitive state. Change: mean score at Week 12 LOCF minus mean score at baseline. Values at final evaluation were imputed using a Last Observation Carried Forward (LOCF) method.

    Time frame: Baseline and every 4 weeks up to 12 weeks

  2. Psychiatric Symptoms: Change From Baseline in Neuropsychiatric Inventory (NPI) Total at Week 12 Last Observation Carried Forward (LOCF)

    NPI measured 10 different domains of psychiatric symptoms including delusion and hallucination. Each domain is scored for: present or absent, frequency, and severity. The score derived from sub-scores; total ranged from "0" to "120," higher score indicated "worse neuropsychiatric outcomes." Change: mean score at Week 12 LOCF minus mean score at baseline. Values at final evaluation were imputed using a Last Observation Carried Forward (LOCF) method.

    Time frame: Baseline and every 4 weeks up to 12 weeks

  3. Global Clinical Function: Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus) Total at Week 12 Last Observation Carried Forward (LOCF)

    CIBIC plus is a clinician's interview-based impression of change plus the caregiver's input. It is a seven-point categorical assessment scale for evaluating global clinical function, ranging from "markedly improved" to "markedly worse". Percentage of participants in each category were reported. Values at final evaluation were imputed using a Last Observation Carried Forward (LOCF) method.

    Time frame: Baseline and week 12

  4. Burden on Caregiver: Change From Baseline in J-ZBI (Japanese- Zarit Caregiver Burden Interview) Total at Week 12 Last Observation Carried Forward (LOCF)

    J-ZBI is a Japanese version instrument to measure and assess the level of burden experienced by the principal caregivers of participants with dementia. ZBI contains 22 items, in which each statement is scored by the caregiver using a 5-point scale. Response options range from 0 (Never) to 4 (Nearly Always). Total score derived from sub-scores; total ranged from 0-88. Higher scores indicate greater burden. Change: mean score at Week 12 LOCF minus mean score at baseline. Values at final evaluation were imputed using a Last Observation Carried Forward (LOCF) method.

    Time frame: Baseline and Week 12

07

Results

Posted Feb 18, 2013

Participant flow

Participant flow — Overall Study
Milestone3 mg Donepezil Hydrochloride5 mg Donepezil Hydrochloride10 mg Donepezil HydrochloridePlacebo
Started35333734
Completed31313130
Not completed4264
Withdrew: Adverse event3134
Withdrew: Lost to follow-up0010
Withdrew: Withdrawal by subject0120
Withdrew: Protocol violation1000

Outcome measures

PrimaryCognitive Function: Change From Baseline in Mini-mental State Examination (MMSE) Total at Week 12 Last Observation Carried Forward (LOCF)

MMSE measured general cognitive functioning: orientation, memory, attention, calculation, language, visuospatial functions. Total score derived from sub-scores; total ranged from 0 - 30, where a higher score indicated better cognitive state. Change: mean score at Week 12 LOCF minus mean score at baseline. Values at final evaluation were imputed using a Last Observation Carried Forward (LOCF) method.

Time frame:
Baseline and every 4 weeks up to 12 weeks
Reported as:
Mean · Score on a scale
Cognitive Function: Change From Baseline in Mini-mental State Examination (MMSE) Total at Week 12 Last Observation Carried Forward (LOCF)
Score on a scale3 mg Donepezil Hydrochloride5 mg Donepezil Hydrochloride10 mg Donepezil HydrochloridePlacebo
Baseline20.1 ± 4.219.7 ± 4.419.7 ± 4.518.2 ± 4.8
Change from Baseline (LOCF)1.2 ± 3.83.5 ± 3.22.3 ± 3.2-0.6 ± 2.7
PrimaryPsychiatric Symptoms: Change From Baseline in Neuropsychiatric Inventory (NPI) Total at Week 12 Last Observation Carried Forward (LOCF)

NPI measured 10 different domains of psychiatric symptoms including delusion and hallucination. Each domain is scored for: present or absent, frequency, and severity. The score derived from sub-scores; total ranged from "0" to "120," higher score indicated "worse neuropsychiatric outcomes." Change: mean score at Week 12 LOCF minus mean score at baseline. Values at final evaluation were imputed using a Last Observation Carried Forward (LOCF) method.

Time frame:
Baseline and every 4 weeks up to 12 weeks
Reported as:
Mean · Score on a scale
Psychiatric Symptoms: Change From Baseline in Neuropsychiatric Inventory (NPI) Total at Week 12 Last Observation Carried Forward (LOCF)
Score on a scale3 mg Donepezil Hydrochloride5 mg Donepezil Hydrochloride10 mg Donepezil HydrochloridePlacebo
Baseline20.9 ± 13.114.2 ± 8.419.1 ± 11.818.4 ± 8.9
Change from Baseline (LOCF)-4.3 ± 21.5-5.9 ± 6.5-10.2 ± 12.0-3.1 ± 10.9
PrimaryGlobal Clinical Function: Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus) Total at Week 12 Last Observation Carried Forward (LOCF)

CIBIC plus is a clinician's interview-based impression of change plus the caregiver's input. It is a seven-point categorical assessment scale for evaluating global clinical function, ranging from "markedly improved" to "markedly worse". Percentage of participants in each category were reported. Values at final evaluation were imputed using a Last Observation Carried Forward (LOCF) method.

Time frame:
Baseline and week 12
Reported as:
Number · Percentage of Participants
Global Clinical Function: Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus) Total at Week 12 Last Observation Carried Forward (LOCF)
Percentage of Participants3 mg Donepezil Hydrochloride5 mg Donepezil Hydrochloride10 mg Donepezil HydrochloridePlacebo
Marked improvement3.617.93.80
Moderate Improvement17.917.911.53.7
Minimal Improvement50.035.750.029.6
No Change21.414.330.818.5
Minimal Worsening3.67.13.837.0
Moderate Worsening07.1011.1
Marked Worsening3.6000
PrimaryBurden on Caregiver: Change From Baseline in J-ZBI (Japanese- Zarit Caregiver Burden Interview) Total at Week 12 Last Observation Carried Forward (LOCF)

J-ZBI is a Japanese version instrument to measure and assess the level of burden experienced by the principal caregivers of participants with dementia. ZBI contains 22 items, in which each statement is scored by the caregiver using a 5-point scale. Response options range from 0 (Never) to 4 (Nearly Always). Total score derived from sub-scores; total ranged from 0-88. Higher scores indicate greater burden. Change: mean score at Week 12 LOCF minus mean score at baseline. Values at final evaluation were imputed using a Last Observation Carried Forward (LOCF) method.

Time frame:
Baseline and Week 12
Reported as:
Mean · Score on a scale
Burden on Caregiver: Change From Baseline in J-ZBI (Japanese- Zarit Caregiver Burden Interview) Total at Week 12 Last Observation Carried Forward (LOCF)
Score on a scale3 mg Donepezil Hydrochloride5 mg Donepezil Hydrochloride10 mg Donepezil HydrochloridePlacebo
Baseline28.3 ± 14.423.2 ± 11.626.9 ± 16.322.3 ± 9.8
Change from Baseline (LOCF)-1.3 ± 11.1-0.6 ± 16.4-5.2 ± 13.82.9 ± 9.1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
3 mg Donepezil Hydrochloride—2/35 (5.7%)24/35 (68.6%)
5 mg Donepezil Hydrochloride—2/33 (6.1%)27/33 (81.8%)
10 mg Donepezil Hydrochloride—4/37 (10.8%)32/37 (86.5%)
Placebo—2/34 (5.9%)24/34 (70.6%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
Event3 mg Donepezil Hydrochloride5 mg Donepezil Hydrochloride10 mg Donepezil HydrochloridePlacebo
ParaparesisNervous system disorders0/351/330/370/34
Inguinal HerniaGastrointestinal disorders0/351/330/370/34
RestlessnessPsychiatric disorders0/350/330/371/34
Diabetic NeuropathyNervous system disorders0/350/330/371/34
Pelvic FractureInjury, poisoning and procedural complications0/350/330/371/34
HallucinationPsychiatric disorders1/350/331/370/34
Cerebral InfarctionNervous system disorders1/350/330/370/34
Subarachnoid HaemorrhageNervous system disorders1/350/330/370/34
PyelonephritisInfections and infestations0/350/331/370/34
Back PainMusculoskeletal and connective tissue disorders0/350/331/370/34
Most frequent other events
Showing 10 of 26
Most frequent other events
Event3 mg Donepezil Hydrochloride5 mg Donepezil Hydrochloride10 mg Donepezil HydrochloridePlacebo
Blood Creatine Phosphokinase IncreasedInvestigations5/353/335/372/34
Blood Pressure IncreasedInvestigations5/352/332/371/34
DiarrhoeaGastrointestinal disorders0/354/333/374/34
NasopharyngitisInfections and infestations3/352/334/371/34
Blood Urine PresentInvestigations0/352/334/373/34
White Blood Cell Count DecreasedInvestigations0/350/334/371/34
ConstipationGastrointestinal disorders0/353/331/371/34
Back PainMusculoskeletal and connective tissue disorders2/351/332/373/34
Blood Triglycerides IncreasedInvestigations2/351/330/373/34
Blood Alkaline Phosphatase IncreasedInvestigations0/350/331/373/34

Baseline characteristics

Age Continuous
Age Continuous(years)3 mg Donepezil Hydrochloride5 mg Donepezil Hydrochloride10 mg Donepezil HydrochloridePlaceboTotal
Mean79.6 ± 4.577.9 ± 6.778.4 ± 6.178.7 ± 4.978.7 ± 5.6
Sex: Female, Male
Sex: Female, Male(Participants)3 mg Donepezil Hydrochloride5 mg Donepezil Hydrochloride10 mg Donepezil HydrochloridePlaceboTotal
Female1816332390
Male171741149
08

Study locations

43 sites
  • Nagoya, Aichi, Japan
  • Obu, Aichi, Japan
  • Toyokawa, Aichi, Japan
  • Kurume, Fukuoka, Japan
  • Omuta, Fukuoka, Japan
  • Maebashi, Gunma, Japan
  • Miyoshi, Hiroshima, Japan
  • Otake, Hiroshima, Japan
  • Himeji, Hyogo, Japan
  • Kobe, Hyogo, Japan
  • Tsukuba, Ibaraki, Japan
  • Kahoku, Ishikawa, Japan
  • Morioka, Iwate, Japan
  • Yokohama, Kanagawa, Japan
  • Nankoku, Kochi, Japan
  • Koshi, Kumamoto, Japan
  • Joyo, Kyoto, Japan
  • Sendai, Miyagi, Japan
  • Komoro, Nagano, Japan
  • Kashihara, Nara, Japan
  • Joetsu, Niigata, Japan
  • Sanjo, Niigata, Japan
  • Yufu, Oita, Japan
  • Sakai, Osaka, Japan
  • Suita, Osaka, Japan
  • Izumo, Shimane, Japan
  • Bunkyo-ku, Tokyo, Japan
  • Kodaira, Tokyo, Japan
  • Koto-ku, Tokyo, Japan
  • Ota-ku, Tokyo, Japan
  • Setagaya-ku, Tokyo, Japan
  • Shinjuku-ku, Tokyo, Japan
  • Ube, Yamaguchi, Japan
  • Akita, Japan
  • Chiba, Japan
  • Fukui, Japan
  • Fukuoka, Japan
  • Kochi, Japan
  • Kumamoto, Japan
  • Kyoto, Japan
  • Osaka, Japan
  • Saitama, Japan
  • Shizuoka, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2013, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2007
First posted
Oct 15, 2007
Start
Nov 2007
Primary completionActual
Feb 2010
CompletionActual
Feb 2010
Results first posted
Feb 18, 2013
Last update
Mar 8, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00543855
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Oct 15, 2007
Start date
Nov 2007
Primary completion
Feb 2010
Completion
Feb 2010
Results posted
Feb 18, 2013
Last update
Mar 8, 2013

Study contacts

Masaki Nakagawa
study director · Neurosciences Clinical Development Section, Japan / Asia Clinical Research, Product Creation Unit, Eisai Product Creation System.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion